Key facts
- It has raised $5.0M; the latest was Seed Round ($5.0M) in Feb 2025.
- Notable investors include PacBridge Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Avitia
- ·The full record, as it builds
Funding rounds
No funding rounds for Avitia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avitia
Developer of artificial intelligence-based molecular diagnostics technology designed to support genomic analysis for cancer detection. The company provides next-generation sequencing panels, distributed bioinformatics analysis, mutation detection tools, and laboratory workflow integration, enabling clinical laboratories and oncology researchers to perform molecular testing and analyze genomic data for cancer research and diagnostics.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2024
- Website
- avitia.bio/
- Ownership
- Privately Held (backing)
Avitia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avitia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avitia in its N-PORT filings yet. We sweep new filings monthly.